Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Vistagen Therapeutics, Inc.

Ticker
VTGN
Sector
Industry
Report date
November 14, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments for Vistagen include regulatory updates following FDA meetings on Phase 3 development of fasedienol, financial results reporting narrower losses, and strategic portfolio activity by investors.

Recent developments:
  • Vistagen announced a regulatory update following a Type C meeting with the FDA regarding Phase 3 development of fasedienol, indicating ongoing regulatory engagement and refinement of the clinical development plan [N1].
  • SRX Global liquidated two portfolio investments and added Onconetix, with Vistagen mentioned in the context of portfolio adjustments [N2].
  • The company reported a narrower Q1 loss and plans for an FDA meeting to discuss the development path for fasedienol [N3].
  • In a weekly industry update, Vistagen missed its clinical development goals, reflecting challenges in advancing its pipeline [N4].
  • Vistagen named Nick Tressler as CFO in December 2025, indicating management changes [N3].
Overview

Vistagen Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company specializing in the development of novel neuroscience therapeutics based on pherine compounds. The company's lead product candidate, fasedienol, is undergoing Phase 3 clinical trials targeting social anxiety disorder. Vistagen has experienced setbacks in prior Phase 3 trials and is currently refining its development strategy for fasedienol, including plans for an event-driven, repeated dosing trial with the LSAS as the primary endpoint. The company has no approved products or commercial revenues and relies on external financing to fund operations and clinical development. Financial disclosures as of September 30, 2026, show limited cash reserves and ongoing net losses. Vistagen's business model is highly dependent on successful clinical development, regulatory approvals, and securing additional capital.

Executive summary

Vistagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing pherine-based neuroscience drug candidates, with its lead candidate fasedienol in Phase 3 development for social anxiety disorder. The company has no approved products or recurring revenues and has incurred significant net losses, including a net loss of $10.7 million for the quarter ended September 30, 2026. Financial disclosures indicate cash and equivalents of $10.9 million and a current ratio of 2.64 as of September 30, 2026. Vistagen faces substantial risks including the need for additional financing, clinical trial uncertainties, and regulatory challenges. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for VTGN

Bull case model:

The bull case for Vistagen centers on the potential of its pherine-based drug candidates, particularly fasedienol, to address unmet needs in social anxiety disorder. Positive preliminary Phase 3 data and ongoing regulatory engagement with the FDA suggest progress in clinical development. If the company successfully completes its refined Phase 3 trial and obtains regulatory approval, it could establish a novel treatment option in a challenging therapeutic area. The proprietary nature of its pherine technology and focused neuroscience pipeline may provide differentiation in the market.

Bear case model:

The bear case highlights the significant risks faced by Vistagen, including repeated failures in prior Phase 3 trials and the absence of approved products or revenues. The company has substantial doubt about its ability to continue as a going concern without additional financing. Clinical development delays, regulatory hurdles, and competitive pressures pose ongoing challenges. Failure to secure sufficient capital or to demonstrate efficacy and safety in pivotal trials could materially harm the company's prospects and financial condition.

Moat:

Vistagen's moat is primarily based on its proprietary pherine technology platform and its lead candidate fasedienol targeting social anxiety disorder, a condition with limited effective treatments. The company's specialized focus on neuroscience and pherine compounds provides a niche scientific approach. However, as a clinical-stage biopharmaceutical company with no approved products, its moat is contingent on successful clinical development, regulatory approval, and eventual commercialization. The company faces competition from other neuroscience drug developers and the inherent risks of drug development, which may limit the durability of its competitive advantage until product approval and market acceptance are achieved.

Risks overview
Risks summary
The most significant risk for Vistagen is its need for additional financing to continue clinical development and operations amid repeated trial failures and regulatory uncertainties.
Risks details:

• Financing Risk: Vistagen requires substantial additional financing to continue operations and clinical development. Failure to secure funding could lead to curtailment of operations or liquidation.
• Clinical Development Risk: The company has experienced failures in Phase 3 trials and faces risks of delays, negative or inconclusive results, and inability to meet regulatory endpoints.
• Regulatory Risk: Obtaining regulatory approval is uncertain and subject to FDA review, additional data requests, and compliance with manufacturing and clinical standards.
• Operational Risk: Dependence on third-party collaborators for clinical trials and manufacturing introduces risks related to performance and compliance.
• Market and Competitive Risk: The neuroscience drug development field is highly competitive and challenging, with limited prior success and potential competing products.

FINAL FORECAST FOR VTGN

Final take one line
Vistagen Therapeutics is a clinical-stage biopharmaceutical company with high visibility into its development challenges, regulatory interactions, and financial risks centered on its lead candidate fasedienol.
Final take 12 to 24 month view

Business trends: Continued focus on advancing fasedienol through refined Phase 3 clinical development with regulatory engagement and addressing social anxiety disorder treatment needs.
Execution milestones: Completion of FDA meetings, initiation and conduct of event-driven Phase 3 trials, and securing additional financing to support operations.
Key risks: Clinical trial failures, regulatory approval uncertainties, financing challenges, and competitive pressures in neuroscience drug development.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • Vistagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel neuroscience drug candidates, primarily pherine compounds.
  • The company has no approved products and has not generated revenue from product sales to date.
  • Its lead product candidate is fasedienol, which is in Phase 3 clinical development for treatment of social anxiety disorder (SAD).
  • Vistagen is refining its Phase 3 development plan for fasedienol from acute treatment of SAD to overall treatment of SAD, planning an event-driven, repeated as-needed dosing Phase 3 clinical trial with the LSAS as the primary efficacy endpoint.
  • The company has experienced failures in prior Phase 3 trials (PALISADE-1, PALISADE-3, PALISADE-4) and a Repeat Dose Study, all failing to meet primary efficacy endpoints.
  • Vistagen reported narrower Q1 losses and plans FDA meetings to discuss the development path for fasedienol.
  • The company reported preliminary positive Phase 3 extension study data and positive findings supporting fasedienol's potential in very severe SAD.
  • Vistagen's financials as of September 30, 2026, include cash and equivalents of $10.9 million, current assets of $22.3 million, current liabilities of $8.4 million, a current ratio of 2.64, and a cash ratio of 1.29.
  • The company reported a net loss of $10.7 million and basic and diluted EPS of -$0.24 for the quarter ended September 30, 2026.
  • Vistagen has stated substantial doubt about its ability to continue as a going concern and requires additional financing to continue operations and development.
  • The company depends heavily on the success of fasedienol and other pherine candidates, with significant risks related to clinical trial outcomes, regulatory approvals, and financing.
  • Vistagen has no recurring revenues and has incurred significant net losses since inception, with losses increasing as it advances clinical development.
  • The company faces risks including delays or failures in clinical trials, regulatory challenges, competition, and the need for substantial additional capital.
  • Recent news includes a regulatory update following a Type C meeting with the FDA on Phase 3 development of fasedienol, indicating ongoing regulatory engagement.
  • SRX Global, an investor, liquidated two portfolio investments and added Onconetix, with Vistagen mentioned in the context of portfolio activity.
  • The company reported narrower Q1 loss and plans for FDA meetings on fasedienol development path.
  • Vistagen missed goals in a weekly industry update, reflecting challenges in clinical progress.
  • The company has named Nick Tressler as CFO in December 2025.
  • Vistagen's recent news coverage spans regulatory updates, clinical trial data releases, financial results, and strategic developments.
Sources
Sources - Context summary

Generated 2026-11-14

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-06-15 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-11-09 | www.nasdaq.com | Vistagen Therapeutics, Inc. Announces Regulatory Update Following Type C Meeting with FDA on Phase 3 Development of Fasedienol | https://www.nasdaq.com/articles/vistagen-therapeutics-inc-announces-regulatory-update-following-type-c-meeting-fda-phase-3
  • N2 | 2026-09-25 | www.nasdaq.com | SRX Global Liquidates 2 Portfolio Investments, Adds Onconetix Ahead Of Realbotix Deal | https://www.nasdaq.com/articles/srx-global-liquidates-2-portfolio-investments-adds-onconetix-ahead-realbotix-deal
  • N3 | 2026-08-14 | www.nasdaq.com | Vistagen Reports Narrower Q1 Loss; Plans FDA Meeting On Fasedienol Development Path | https://www.nasdaq.com/articles/vistagen-reports-narrower-q1-loss-plans-fda-meeting-fasedienol-development-path
  • N4 | 2026-07-02 | www.nasdaq.com | Weekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goal | https://www.nasdaq.com/articles/weekly-buzz-vrtx-aptx-gain-fda-nod-uncy-disappoints-ipsen-opens-wallet-vtgn-misses-goal
  • N5 | 2026-06-03 | www.nasdaq.com | Veeva Systems (VEEV) Q1 Earnings and Revenues Surpass Estimates | https://www.nasdaq.com/articles/veeva-systems-veev-q1-earnings-and-revenues-surpass-estimates
  • N6 | 2026-05-28 | www.nasdaq.com | HealthEquity (HQY) Q1 Earnings and Revenues Top Estimates | https://www.nasdaq.com/articles/healthequity-hqy-q1-earnings-and-revenues-top-estimates
  • N7 | 2026-05-20 | www.nasdaq.com | Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/roivant-sciences-ltd-roiv-reports-q4-loss-misses-revenue-estimates
  • N8 | 2026-05-18 | www.nasdaq.com | Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/compugen-cgen-reports-q1-loss-lags-revenue-estimates
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine